Leukemia initiated by PMLRARα: The PML domain plays a critical role while retinoic acid-mediated transactivation is dispensable

Blood

Volumn 95, Issue 5, 2000, Pages 1541-1550

  Kogan, Scott C ^a   Hong, Suk Hyun ^b   Shultz, David B ^b   Privalsky, Martin L ^b   Bishop, J Michael ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE; RETINOIC ACID; RETINOIC ACID RECEPTOR; ANTINEOPLASTIC AGENT; HYBRID PROTEIN; ONCOPROTEIN; PROMYELOCYTIC LEUKEMIA RETINOIC ACID RECEPTOR ALPHA FUSION ONCOPROTEIN; PROMYELOCYTIC LEUKEMIA-RETINOIC ACID RECEPTOR ALPHA FUSION ONCOPROTEIN; REPRESSOR PROTEIN; TUMOR PROTEIN;

ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; FUSION GENE; LEUKEMIA CELL; LEUKEMOGENESIS; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSACTIVATION; TRANSGENIC MOUSE; ANIMAL; CELL DIFFERENTIATION; CELL TRANSFORMATION; CERCOPITHECUS; CHEMISTRY; DISEASE COURSE; DOMINANT GENE; DRUG EFFECT; EXPERIMENTAL LEUKEMIA; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; MUTAGENESIS; PATHOLOGY; PHYSIOLOGY; PROMYELOCYTIC LEUKEMIA; PROTEIN TERTIARY STRUCTURE; RADIATION CHIMERA;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; CERCOPITHECUS AETHIOPS; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, LEUKEMIC; GENES, DOMINANT; HUMANS; LEUKEMIA, EXPERIMENTAL; LEUKEMIA, PROMYELOCYTIC, ACUTE; MICE; MICE, TRANSGENIC; MUTAGENESIS; NEOPLASM PROTEINS; ONCOGENE PROTEINS, FUSION; PHENOTYPE; PROTEIN STRUCTURE, TERTIARY; RADIATION CHIMERA; RECOMBINANT FUSION PROTEINS; REPRESSOR PROTEINS; TRANS-ACTIVATION (GENETICS); TRANSFECTION; TRETINOIN;

EID: 0034144710     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.5.1541.005k28_1541_1550     Document Type: Article

References (74)

1. Spom MB, Roberts AB, Goodman DS. The Retinoids: Biology, Chemistry, and Medicine. 2nd ed. New York, NY: Raven; 1994.
2. Kastner P, Mark M, Chambon P. Nonsteroid nuclear receptors: what are genetic studies telling us about their role in real life? Cell. 1995;83:859-869.
3. Smith MA, Parkinson DR, Cheson BD, Friedman MA. Retinoids in cancer therapy. J Clin Oncol. 1992;10:839-864.
4. Redfern CP, Lovat PE, Malcolm AJ, Pearson AD. Gene expression and neuroblastoma cell differentiation in response to retinoic acid: differential effects of 9-cis and all-trans retinoic acid. Eur J Cancer. 1995;31A:486-494.
5. Breitman TR, Collins SJ, Keene BR. Terminal differentiation of human promyelocytic leukemic cells in primary culture in response to retinoic acid. Blood. 1981;57:1000-1004.
6. Huang ME, Ye YC, Chen SR, et al. All-trans retinoic acid with or without low dose cytosine arabinoside in acute promyelocytic leukemia. Report of 6 cases. Chin Med J (Engl). 1987;100:949-953.
7. Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988;72:567-572.
8. Rowley JD, Golomb HM, Dougherty C. 15/17 translocation, a consistent chromosomal change in acute promyelocylic leukaemia. Lancet. 1977;1:549-550.
9. de The H, Chomienne C, Lanotte M, Degos L, Dejean A. The t(15;17) translocation of acute promyelocylic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature. 1990;347:558-561.
10. Borrow J, Goddard AD, Sheer D, Solomon E. Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. Science. 1990;249:1577-1580.
11. Alcalay M, Zangrilli D, Pandolfi PP, et al. Translocation breakpoint of acute promyelocytic leukemia lies within the retinoic acid receptor alpha locus. Proc Natl Acad Sci USA. 1991;88:1977-1981.
12. Lemons RS, Eilender D, Waldmann RA, et al. Cloning and characterization of the t(15;17) translocation breakpoint region in acute promyelocytic leukemia. Genes Chromosomes Cancer. 1990;2:79-87.
13. Kakizuka A, Miller W Jr, Umesono K, et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell. 1991;66:663-674.
14. Goddard AD, Borrow J, Freemont PS, Solomon E. Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia. Science. 1991;254:1371-1374.
15. de The H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell. 1991;66:675-684.
16. Pandolfi PP, Alcalay M, Fagioli M, et al. Genomic variability and alternative splicing generate multiple PML/RAR alpha transcripts that encode aberrant PML proteins and PML/RAR alpha isoforms in acute promyelocytic leukaemia. Embo J. 1992;11:1397-1407.
17. Kastner P, Perez A, Lutz Y, et al. Structure, localization and transcriptional properties of two classes of retinoic acid receptor alpha fusion proteins in acute promyelocytic leukemia (APL): structural similarities with a new family of oncoproteins. Embo J. 1992;11:629-642.
18. Pandolfi P. PML, PLZF and NPM genes in the molecular pathogensis of acute promyelocytic leukemia. Haematologica. 1996;81:472-482.
19. Chen Z, Brand NJ, Chen A, et al. Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia. Embo J. 1993;12:1161-1167.
20. Redner RL, Rush EA, Faas S, Rudert WA, Corey SJ. The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. Blood. 1996;87:882-886.
21. Wells RA, Catzavelos C, Kamel-Reid S. Fusion at retinoic acid receptor alpha to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia. Nat Genet. 1997;17:109-113.
22. Mangelsdorf DJ, Evans RM. The RXR heterodimers and orphan receptors. Cell. 1995,83:841-850.
23. Rousselot P, Hardas B, Patel A, et al. The PML-RAR alpha gene product of the t(15;17) translocation inhibits retinoic acid-induced granulocytic differentiation and mediated transactivation in human myeloid cells. Oncogene. 1994;9:545-551.
24. Pandolfi PP, Grignani F, Alcalay M, et al. Structure and origin of the acute promyelocytic leukemia myl/RAR alpha cDNA and characterization of its retinoid-binding and transactivation properties. Oncogene. 1991;6:1285-1292.
25. Ruthardt M, Testa U, Nervi C, et al. Opposite effects of the acute promyelocytic leukemia PML-retinoic acid receptor alpha (RAR alpha) and PLZF-RAR alpha fusion proteins on retinoic acid signalling. Mol Cell Biol. 1997;17:4859-4869.
26. Degos L, Dombret H, Chomienne C, et al. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood. 1995;85:2643-2653.
27. Warrell RP Jr, Maslak P, Eardley A, et al. Treatment of acute promyelocytic leukemia with all-trans retinoic acid: an update of the New York experience. Leukemia. 1994;8:929-933.
28. Ding W, Li YP, Nobile LM, et al. Leukemic cellular retinoic acid resistance and missense mutations in the PML-RARalpha fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapy. Blood. 1998;92:1172-1183.
29. Imaizumi M, Suzuki H, Yoshinari M, et al. Mutations in the E-domain of RAR portion of the PML/ RAR chimeric gene may confer clinical resistance to all-trans retinoic acid in acute promyelocytic leukemia. Blood. 1998;92:374-382.
30. Kitamura K, Kiyoi H, Yoshida H, Saito H, Ohno R, Naoe T. Mutant AF-2 domain of PML-RARalpha in retinoic acid-resistant NB4 cells: differentiation induced by RA is triggered directly through PML-RARalpha and its down-regulation in acute promyelocytic leukemia. Leukemia. 1997;11:1950-956.
31. Shao W, Benedetti L, Lamph WW, Nervi C, Miller WH Jr. A retinoid-resistant acute promyelocytic leukemia subclone expresses a dominant negative PML-RAR alpha mutation. Blood. 1997;89:4282-4289.
32. Brown D, Kogan S, Lagasse E. et al. A PMLRAR alpha transgene initiates murine acute promyelocytic leukemia. Proc Natl Acad Sci USA. 1997;94:2551-2556.
33. Sande S, Privalsky ML. Identification of TRACs (T3 receptor-associating cofactors), a family of cofactors that associate with, and modulate the activity of, nuclear hormone receptors. Mol Endocrinol. 1996;10:813-825.
34. Hong SH, David G, Wong CW, Dejean A, Privalsky ML. SMRT corepressor interacts with PLZF and with the PML-retinoic acid receptor alpha (RARalpha) and PLZF-RARalpha oncoproteins associated with acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 1997;94:9028-9033.
35. Hong SH, Privalsky ML. Retinoid isomers differ in the ability to induce release of SMRT corepressor from retinoic acid receptor-alpha. J Biol Chem. 1999;274:2885-2892.
36. Lagasse E, Weissman IL. bcl-2 inhibits apoptosis of neutrophils but not their engulfment by macrophages. J Exp Med. 1994;179:1047-1052.
37. Hogan B, Constantini F, Lacy E. Manipulating the Mouse Embryo: A Laboratory Manual. 2nd ed. Plainview, NY: Cold Spring Harbor Laboratory Press:1994.
38. Taketo M, Schroeder AC, Mobraaten LE, et al. FVB/N: an inbred mouse strain preferable for transgenic analyses. Proc Natl Acad Sci USA. 1991;88:2065-2069.
39. Robbins SM, Quintrell NA, Bishop JM. Myristoylation and differential palmitoylation of the HCK protein-tyrosine kinases govern their attachment to membranes and association with caveolae. Mol Cell Biol. 1995;15:3507-3515.
40. Kogan SC, Lagasse E, Atwater S, et al. The PEBP2betaMYH11 fusion created by Inv(16)(p13;q22) in myeloid leukemia impairs neutrophil maturation and contributes to granulocytic dysplasia. Proc Natl Acad Sci USA. 1998;95:11,863-11, 868.
41. Karasuyama H, Melchers F. Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 or 5, using modified cDNA expression vectors. Eur J Immunol. 1988;18:97-104.
42. Lin RJ, Nagy L, Inoue S, Shao W, Miller WH Jr, Evans RM. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature. 1998;391:811-814.
43. Keidel S, LeMotte P, Apfel C. Different agonist-and antagonist-induced conformational changes in retinoic acid receptors analyzed by protease mapping. Mol Cell Biol. 1994;14:287-298.
44. Leng X, Tsai SY, O'Malley BW, Tsai MJ. Ligand-dependent conformational changes in thyroid hormone and retinoic acid receptors are potentially enhanced by heterodimerization with retinoic X receptor. J Steroid Biochem Mol Biol. 1993;46:643-661.
45. Grignani F, De Matteis S, Nervi C, et al. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature. 1998;391:815-818.
46. Lallemand-Breitenbach V, Guillemin MC, Janin A, et al. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med. 1999;189:1043-1052.
47. Grisolano JL, Wesselschmidt RL, Pelicci PG, Ley TJ. Altered myeloid development and acute leukemia in transgenic mice expressing PML-RAR alpha under control of cathepsin G regulatory sequences. Blood. 1997;89:376-387.
48. He LZ, Tribioli C, Rivi R, et al. Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice. Ptoc Natl Acad Sci U S A. 1997;94:5302-5307.
49. Rabbitts TH. Chromosomal translocations in human cancer. Nature. 1994;372:143-149.
50. Look AT. Oncogenic transcription factors in the human acute leukemias. Science. 1997;278:1059-1064
51. Grignani F, Ferrucci PF, Testa U, et al. The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell. 1993;74:423-431.
52. Grignani F, Testa U, Rogaia R, et al. Effects on differentiation by the promyelocytic leukemia PML/RAR alpha protein depend on the fusion of the PML protein dimerization and RAR alpha DNA binding domain. Embo J. 1996;15:4949-4958.
53. Chen SJ, Zelent A, Tong JH, et al. Rearrangements of the retinoic acid receptor alpha and promyelocytic leukemia zinc finger genes resulting from t(11;17)(q23;q21) in a patient with acute promyelocytic leukemia. J Clin Invest. 1993;91:2260-2267.
54. Licht JD, Chomienne C, Goy A, et al. Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood. 1995;85:1083-1094.
55. Chen Z, Guidez F, Rousselot P, et al. PLZF-RAR alpha fusion proteins generated from the variant t(11;17)(q23;q21) translocation in acute promyelocytic leukemia inhibit ligand-dependent transactivation of wild-type retinoic acid receptors. Proc Natl Acad Sci USA. 1994;91:1178-1182.
56. He LZ, Guidez F, Tribioli C, et al. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nat Genet. 1998;18:126-135.
57. Purton LE, Bernstein ID, Collins SJ. All-trans retinoic acid delays the differentiation of primitive hematopoietic precursors (lin-c-kit + Sca-1(+)) while enhancing the terminal maturation of committed granulocyte/monocyte progenitors. Blood. 1999;94:483-495.
58. Douer D, Koeffler HP. Retinoic acid enhances colony-stimulating factor-induced clonal growth of normal human myeloid progenitor cells in vitro. Exp Cell Res. 1982;138:193-198.
59. Gratas C, Menot ML, Dresch C, Chomienne C. Retinoid acid supports granulocylic but not erythroid differentiation of myeloid progenitors in normal bone marrow cells. Leukemia. 1993;7:1156-1162.
60. Tsai S, Collins SJ. A dominant negative retinoic acid receptor blocks neutrophil development at the promyelocyte stage. Proc Natl Acad Sci USA. 1993;90:7153-7157.
61. Guidez F, Ivins S, Zhu J, Soderstrom M, Waxman S, Zelent A. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia. Blood. 1998;91:2634-2642.
62. Mu ZM, Chin KV, Liu JH, Lozano G, Chang KS. PML, a growth suppressor disrupted in acute promyelocytic leukemia. Mol Cell Biol. 1994;14:6858-6867.
63. Koken MH, Linares-Cruz G, Quignon F, et al. The PML growth-suppressor has an altered expression in human oncogenesis. Oncogene. 1995;10:1315-1324.
64. Borden KL, Campbell-Dwyer EJ, Salvato MS. The promyelocytic leukemia protein PML has a pro-apoptotic activity mediated through its RING domain. FEBS Lett. 1997;418:30-34.
65. Le XF, Vallian S, Mu ZM, Hung MC, Chang KS. Recombinant PML adenovirus suppresses growth and tumorigenicity of human breast cancer cells by inducing G1 cell cycle arrest and apoptosis. Oncogene. 1998;16:1839-1849.
66. Wang ZG, Delva L, Gaboli M, et al. Role of PML in cell growth and the retinoic acid pathway. Science. 1998;279:1547-1551.
67. Wang ZG, Ruggero D, Ronchetti S, et al. PML is essential for multiple apoptotic pathways Nat Genet. 1998;20:266-272.
68. Wang ZG, Rego E, Penuzzi D, He LZ, Pandolfi PP. Loss of PML function enhances the frequency and onset of APL in PML-RARalpha transgenic mice. Blood. 1998;92:S1,479a.
69. Perez A, Kastner P, Sethi S, Lutz Y, Reibel C, Chambon P. PMLRAR homodimers: distinct DNA binding properties and heteromeric interactions with RXR. Embo J. 1993;12:3171-3182.
70. Jansen JH, Mahfoudi A, Rambaud S, Lavau C, Wahli W, Dejean A. Multimeric complexes of the PML-retinoic acid receptor alpha fusion protein in acute promyelocytic leukemia cells and interference with retinoid and peroxisome-proliferator signaling pathways. Proc Natl Acad Sci U S A. 1995;92:7401-7405.
71. Du C, Redner RL, Cooke MP, Lavau C. Overexpression of wild-type retinoic acid receptor alpha (RARalpha) recapitulates retinoic acid-sensitive transformation of primary myeloid progenitors by acute promyelocytic leukemia RARalpha-fusion genes. Blood. 1999;94:793-802.
72. Lavau C, Szilvassy SJ, Slany R, Cleary ML. Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL. Embo J. 1997;16:4226-4237.
73. Dexter TM, Garland J, Scott D, Scolnick E, Metcalf D Growth of factor-dependent hemopoietic precursor cell lines. J Exp Med. 1980;152:1036-1047.
74. Labrecque J, Allan D, Chambon P, Iscove NN, Lohnes D, Hoang T. Impaired granulocytic differentiation in vitro in hematopoietic cells lacking retinoic acid receptors alpha 1 and gamma. Blood. 1998;92:607-615.